Simcere Pharmaceutical Group Raises $65 Million by Selling Its Boda Pharma Subsidiary

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 24, 2013 -- Simcere Pharma of Nanjing agreed to sell its 99.99% stake in Jilin Boda Pharma for 400 million RMB ($65 million). Simcere bought an initial 51% ownership of Boda in 2007 for $15 million. Both Boda and Simcere produce injectible edaravone drugs that act as neuroprotectives following a stroke. The Boda sale has taken place after Simcere’s Chairman offered $503 million to take Simcere private, and the $65 million in sale proceeds will render the take-private deal easier to finance. More details....

Stock Symbol: (NYSE: SCR)

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC